analyses (Hazard Ratio 1.52 [1.17,1.97], p¼0.002). There was no significant association between PRU quintiles and mortality.
Background: High platelet reactivity (HPR) is associated with poor prognosis in coronary artery disease. Recently PLATO subgroup analysis showed that ticagrelor is better clinical outcome than the clopidogrel, which was related with low HPR. Also many studies reported that adjunctive cilostazol to dual antiplatelet therapy (DAPT) (so called triple antiplatelet therapy; TAT) is better clinical outcome than DAPT, which was associated with a greater antiplatelet effect at 30 days. Thus, this study was designed to compare the effect of ticagrelor and TAT on platelet reactivity with PRU and ARU values. Methods: This study was composed of total 65 patients underwent the coronary stenting. All patients received a 600-mg loading dose of clopidogrel or a 180-mg loading dose of ticagrelor and concomitant aspirin therapy. After patients underwent coronary stenting, they were nonrandomly assigned to 1 of 4 groups: DAPT group (n¼15), clopidogrel of 75 mg daily; ticagrelor group (n¼20), ticagrelor of 180 mg daily; TAT group (n¼15), adjunctive cilostazol of 100 mg twice daily to clopidogrel of 75 mg daily; and triple switch group (n¼15), switch of ticagrelor to TAT since 3rd day. The platelet reactivity was assessed by ARU and PRU values at day 2 and day 7, respectively. Results: The average PRU value was lower in ticagrelor and TAT group than DAPT throughout the study period but the average ARU value did not differ among the 4 groups. The 2nd day average ARU was lower in the TAT group than ticagrelor group (405 vs. 510, p<0.01) and there was no significant difference on 7th day average ARU value. In ticagrelor group, 7th day average ARU is lower than 2th day ARU (458 vs. 510, p<0.05) . Compared with TAT group, ticagrelor group had significantly lower PRU level at 2nd day and 7th day, respectively (91 vs. 162, p<0.05, 50 vs. 163, p<0.01) . The 2nd day average PRU value of triple switch group was 70 which was similar to PRU of ticagrelor group and 7th day average PRU (151) was similar to that of TAT group. Conclusions: The ticagrelor and TAT therapy had the lower PRU level than DAPT and especially, ticagrelor showed the lowest incidence of HPR. This indicates that ticagrelor is more effective in HPR treatment than TAT. Background: In patients undergoing PCI for STEMI/NSTEMI, a loading dose (LD) of the new potent P2Y12 inhibitors, thanks to their early onset of platelet inhibition, can be administered immediately after the diagnostic coronary angiography. However, there are no data about the level of platelet inhibition they provide during and immediately after the PCI with this timing of administration. We sought to assess and compare the action of prasugrel, ticagrelor and clopidogrel during and immediately after the PCI for STEMI/NSTEMI when administered with this specific timing. Methods: Seventy-two patients with STEMI/NSTEMI undergoing urgent PCI with heparin monotherapy were randomized after the coronary angiogram to receive 60 mg prasugrel LD (n 24) or ticagrelor 180 mg (n 24) or clopidogrel 600 mg (n 24). Residual platelet reactivity was assessed with VerifyNow at baseline, 30 min and 120 min after the LD. A 24 h platelet reactivity assessment with Light Transmission Aggregometry (LTA) was also performed. Results: Platelet reactivity units (PRU) 30 min after the LD were 305 (AE70), 286 (AE59) and 280 (AE70) in the prasugrel, ticagrelor and clopidogrel group, respectively (p¼ NS). PRU 120 min after the LD were 220 (AE100), 210 (AE88) and 163 (AE101), respectively (overall p 0.1). At 120 min PRU post hoc analysis only clopidogrel Vs ticagrelor were significantly different (p ¼ 0.03). Furthermore, high residual platelet reactivity (HRPR) (PRU > 240) was found in 52%, 28% and 58% of patient in the prasugrel, ticagrelor and clopidogrel group, respectively (p¼ 0.12). No case of HRPR (defined as LTA assessed residual platelet activity > 65%) were found in the prasugrel and ticagrelor group while 55% of patients showed HRPR in the clopidogrel group (p< 0.01). At multivariate analysis no independent predictors of HRPR at 120 min were found. Conclusions: None of the drugs studied achieved an effective platelet inhibition during the PCI when administered immediately after the coronary angiogram in patients with STEMI/NSTEMI. At 120 min only ticagrelor achieved a significantly higher inhibition of platelet reactivity when compared to clopidogrel. A high percentage of HRPR both at 30 min and 120 min was present in all groups.
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The Background: Many patients with coronary artery disease receive concomitant treatment with clopidogrel and calcium channel blockers (CCB). Prior small studies have raised concerns regarding the effect of CCB on clopidogrel-related platelet reactivity and its clinical significance. We examined this relationship in the large scale Assessment of Dual Anti-Platelet Therapy with Drug-Eluting Stents (ADAPT-DES) registry. Methods: A total of 8,583 patients had P2Y12 platelet reactivity testing using the VerifyNow point-of-care assay after successful, non-complicated PCI with DES implantation. All patients were treated with aspirin and clopidogrel, and were followed for 1 year. CCB were prescribed at the discretion of treating physicians. Results: At the time of the post-procedure P2Y12 test, 2437 (28.4%) pts were on CCB, and 6146 (71.6%) were not. Major baseline characteristics, P2Y12 results and 1-year follow-up events are summarized in the Table. The use of CCB was an independent predictor of higher platelet reactivity units (PRU) in a linear regression model (p<0.0001), and was independently associated with high platelet reactivity as defined as PRU >208 (OR 1.16, p¼0.014). At discharge, 1771 (20.6%) pts were prescribed CCB, and 6811 (79.4%) were not. In propensity-stratified proportional hazards regression models, the use of CCB was not independently associated with adverse outcomes. www.jacctctabstracts2013.com TUESDAY, OCTOBER 29, 2013, 3:30 PM-5:30 PM 
